BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 сен 2024 06:00:46 Источник Nasdaq GlobeNewswire

NetDania - New 12 months High: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

03 сен 2024 09:02:32 Источник NetDania Notify

NetDania - New 12 months High: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

29 авг 2024 09:17:26 Источник NetDania Notify

NetDania - New 12 months High: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

28 авг 2024 08:45:07 Источник NetDania Notify

NetDania - New 12 months High: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

26 авг 2024 08:45:03 Источник NetDania Notify

NetDania - New 12 months High: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

23 авг 2024 09:45:41 Источник NetDania Notify

BioCryst to Present at Upcoming Investor Conferences

22 авг 2024 06:00:00 Источник Nasdaq GlobeNewswire

NetDania - New 12 months High: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

09 авг 2024 08:45:50 Источник NetDania Notify

NetDania - New 12 months High: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

07 авг 2024 08:45:08 Источник NetDania Notify

BioCryst Reports Second Quarter 2024 Financial Results and Provides Business Update

05 авг 2024 06:00:24 Источник Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 авг 2024 06:00:47 Источник Nasdaq GlobeNewswire

NetDania - New 12 months High: BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

29 июл 2024 08:56:40 Источник NetDania Notify

BioCryst to Report Second Quarter 2024 Financial Results on August 5

22 июл 2024 06:00:09 Источник Nasdaq GlobeNewswire

ORLADEYO® (berotralstat) Approved in Peru

09 июл 2024 06:00:00 Источник Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 июл 2024 06:00:06 Источник Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 июн 2024 06:00:59 Источник Nasdaq GlobeNewswire

BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) Treatment

02 июн 2024 03:00:13 Источник Nasdaq GlobeNewswire

BioCryst to Present New Data at 2024 Meeting of the European Academy of Allergy and Clinical Immunology

14 май 2024 06:00:53 Источник Nasdaq GlobeNewswire

ORLADEYO® (berotralstat) Approved in Mexico

13 май 2024 06:00:00 Источник Nasdaq GlobeNewswire

BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO® (berotralstat)

09 май 2024 06:00:00 Источник Nasdaq GlobeNewswire